Literature DB >> 16697729

Evidence-based incorporation of serum sodium concentration into MELD.

Scott W Biggins1, W Ray Kim, Norah A Terrault, Sammy Saab, Vijay Balan, Thomas Schiano, Joanne Benson, Terry Therneau, Walter Kremers, Russell Wiesner, Patrick Kamath, Goran Klintmalm.   

Abstract

BACKGROUND & AIMS: Serum sodium (Na) concentrations have been suggested as a useful predictor of mortality in patients with end-stage liver disease awaiting liver transplantation.
METHODS: We evaluated methods to incorporate Na into model for end-stage liver disease (MELD), using a prospective, multicenter database specifically created for validation and refinement of MELD. Adult, primary liver transplant candidates with end-stage liver disease were enrolled.
RESULTS: Complete data were available in 753 patients, in whom the median MELD score was 10.8 and sodium was 137 mEq/L. Low Na (<130 mEq/L) was present in 8% of patients, of whom 90% had ascites. During the study period, 67 patients (9%) died, 243 (32%) underwent transplantation, 73 (10%) were withdrawn, and 370 were still waiting. MELD score and Na, at listing, were significant (both, P < .01) predictors of death within 6 months. After adjustment for MELD score and center, there was a linear increase in the risk of death as Na decreased between 135 and 120 mEq/L. A new score to incorporate Na into MELD was developed: "MELD-Na" = MELD + 1.59 (135 - Na) with maximum and minimum Na of 135 and 120 mEq/L, respectively. In this cohort, "MELD-Na" scores of 20, 30, and 40 were associated with 6%, 16%, and 37% of risk of death within 6 months of listing, respectively. If this new score were used to allocate grafts, it would affect 27% of the transplant recipients.
CONCLUSIONS: We demonstrate an evidence-based method to incorporate Na into MELD, which provides more accurate survival prediction than MELD alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697729     DOI: 10.1053/j.gastro.2006.02.010

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  182 in total

1.  MELD as a metric for survival benefit of liver transplantation.

Authors:  Xun Luo; Joseph Leanza; Allan B Massie; Jacqueline M Garonzik-Wang; Christine E Haugen; Sommer E Gentry; Shane E Ottmann; Dorry L Segev
Journal:  Am J Transplant       Date:  2018-02-19       Impact factor: 8.086

2.  Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Tianyan Chen; Yingli He; Xiaojing Liu; Zhi Yan; Ke Wang; Hongli Liu; Shuling Zhang; Yingren Zhao
Journal:  Clin Exp Med       Date:  2011-10-15       Impact factor: 3.984

3.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

Review 4.  Prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Giacomo Germani; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

5.  The impact of cirrhosis and MELD score on postoperative morbidity and mortality among patients selected for liver resection.

Authors:  Victor M Zaydfudim; Florence E Turrentine; Mark E Smolkin; Todd B Bauer; Reid B Adams; Timothy L McMurry
Journal:  Am J Surg       Date:  2020-01-20       Impact factor: 2.565

6.  Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.

Authors:  Maximilian Jara; Tomasz Dziodzio; Maciej Malinowski; Katja Lüttgert; Radoslav Nikolov; Paul Viktor Ritschl; Robert Öllinger; Johann Pratschke; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2018-11-07       Impact factor: 3.199

Review 7.  What's new in the treatment of ascites and spontaneous bacterial peritonitis.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  Curr Gastroenterol Rep       Date:  2008-02

8.  Impact of the Pediatric End-Stage Liver Disease (PELD) growth failure thresholds on mortality among pediatric liver transplant candidates.

Authors:  Sonja M Swenson; John P Roberts; Sue Rhee; Emily R Perito
Journal:  Am J Transplant       Date:  2019-09-03       Impact factor: 8.086

9.  Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease.

Authors:  M Somsouk; J Guy; S W Biggins; E Vittinghoff; M A Kohn; J M Inadomi
Journal:  Aliment Pharmacol Ther       Date:  2009-07-13       Impact factor: 8.171

10.  Value of MELD and MELD-based indices in surgical risk evaluation of cirrhotic patients: retrospective analysis of 190 cases.

Authors:  Beatriz P Costa; F Castro Sousa; Marco Serôdio; César Carvalho
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.